0.54Open0.54Pre Close0 Volume66 Open Interest7.50Strike Price0.00Turnover103.84%IV-12.62%PremiumDec 20, 2024Expiry Date1.32Intrinsic Value100Multiplier9DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8691Delta0.2173Gamma4.49Leverage Ratio-0.0112Theta-0.0013Rho-3.91Eff Leverage0.0020Vega
Foghorn Therapeutics Stock Discussion
loading...
loading...
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
No comment yet